No, The DEA Did Not Reschedule The CBD Compound

To be clear, unless its FDA approved its schedule hasn’t changed

There is a certain level of confusion reverberating throughout the cannabis community right now over the DEA’s recent decision to make Epidiolex, the cannabis-based epilepsy drug created by GW Pharmaceuticals, a Schedule V controlled substance. Some folks are convinced that since this FDA-approved medication is pure cannabidiol (CBD) that all CBD products fall into the same category.

Sadly, this is not true. The federal government still considers all other cannabis-derived CBD products to be a violation of federal law.

The DEA’s official statement in the Federal Register, which published Friday, indicates “this order places FDA-approved drugs that contain CBD derived from cannabis and no more than 0.1 percent tetrahydrocannabinols in schedule V.”


To Read The Rest Of This Article On Forbes, Click Here


Stay up-to-date!

Get all the news and info straight into your inbox that you need to help grow your business.

To Top